Zelda Therapeutics Ltd. announced it has entered into a binding Heads of Agreement (HoA) with Ilera Healthcare, LLC to explore a broad range of commercialisation opportunities. Ilera is a vertically integrated medicinal cannabis company with operations based in Pennsylvania and Louisiana, USA. Ilera's operations cover the cultivation, processing and dispensing of medicinal cannabis. Ilera customizes products with formulations designed to address the unmet clinical needs of patients. In addition, Ilera is expanding their footprint to other states through license applications and partnerships. Ilera was founded as a science-driven company by executives with extensive experience in the life science capital markets, corporate management and pharmaceutical industries. The chairman Mr. Osagie Imasogie has held senior positions in companies such as GlaxoSmithKline, Endo Pharmaceuticals and DuPont Merck, while Vice Chair Ms Lisa Gray has worked with SmithKline Beecham Pharmaceuticals and GlaxoSmithKline Pharmaceuticals. The founding CEO Gregory Rochlin is a successful entrepreneur and has also served on the boards of medical centres and hospitals. Under the terms of the binding HoA, Zelda and Ilera will explore a range of collaborative and commercialisation opportunities including: co-development of potential full spectrum, uniquely formulated products supported by pharmacokinetic and clinical studies; licensing of clinically validate products; and data-sharing and generation of joint intellectual property. No upfront payments will be received initially however the terms provide for both parties to negotiate separate commercial agreements for the various licensing, co-development and data-sharing opportunities that will be explored under the partnership.